Tada T, Toyoda H, Yasuda S, et al. - Among 254 patients with chronic hepatitis B virus (HBV) who received nucleos(t)ide analogue therapy, researchers simulated the long-term prognosis of liver disease. Investigators found that hepatocellular carcinoma (HCC) development occurred in men with chronic hepatitis in their 50s and at least 70 years and in patients with cirrhosis in all age groups (40–49, 50–59, 60–69, and ≥ 70 years) in the analysis of 1-year liver disease state transition probabilities. In patients with chronic hepatitis in their 50s and 60s and in patients with cirrhosis in their 60s, HBsAg-negative status was present. Findings revealed that there is a risk of developing HCC in middle-aged men with chronic hepatitis or cirrhosis and older women with cirrhosis even when undergoing analogue treatment with nucleos(t)ide.